Kentaro Imai

Statistics

Publications

Citations

136

H-Index

Active since

2018

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD K.K. (Japan)

Macquarie University

Kentaro Imai is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in infectious disease epidemiology, health sciences, and clinical epidemiology.

ORCID

Publications per year

2018–2023

Publications

Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database

Daniel J. Ruzicka, Kentaro Imai, Kenichi Takahashi et al. · BMJ Open · 2018 · 53 citations · Full text

Education, Health Sciences, Clinical Epidemiology +16

Risk of pneumococcal diseases in adults with underlying medical conditions: a retrospective, cohort study using two Japanese healthcare databases

Kentaro Imai, Tanaz Petigara, Melvin A. Kohn et al. · BMJ Open · 2018 · 48 citations · Full text

Veterinary Medicine, Health Sciences, Infectious Diseases +15

1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

Julie N. Graff, Mauricio Burotto, Peter C.C. Fong et al. · Annals of Oncology · 2023 · 25 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564.

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · Journal of Clinical Oncology · 2022 · 10 citations

Medicine, Oncology, Pharmacotherapy +17

1–4 of 4